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a b s t r a c t
Objective: To determine the frequency of antiparvovírus B19 (B19) antibodies in patients 
with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), and the possible 
correlation of anti-B19 seropositivity with disease activity and quality of life.
Patients and methods: Serum samples from 57 patients with RA, 45 with SLE and 65 healthy 
controls were used. We applied protocol with clinical data, and the Disease Activity Score 
28 (DAS 28), Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and Health As-
sessment Questionnaire (HAQ) indexes. The anti-B19 serology was done by enzyme-linked 
immunosorbent assay (ELISA).
Results: The mean age of patients was 42.74 ± 14.09 years, and of controls was 38.38 ± 13.42 
years. 79 patients had active disease (77.5%), and 23 had inactive disease (22.5%). Anti-B19 
(IgG) was positive in 49 (86.0%; CI 95% 77.0 – 95.0) RA patients, 38 (84.4%; CI 95% 73.9 – 95.0) 
SLE patients, and 40 (61.5%; CI 95% 49.7 – 73.4) controls (p = 0.002). Anti-B19 (IgM) was posi-
tive in 3 (5.3%; CI 95% 0.0 – 11.1) RA patients, in 7 (15.6%; CI 95% 5.0 – 26,2) SLE patients, and 
in 1 (1.5%; CI 95% 0.0 – 4.5) control (p = 0.011). There was no correlation of anti-B19 reactivity 
with disease activity and with DAS 28, HAQ and SLEDAI indexes.
Conclusion: This study demonstrated that the studied population is exposed to infection by 
B19, which demands attention with its manifestations, especially among patients at great-
est risk, such as those immunosuppressed.
© 2014 Elsevier Editora Ltda. All rights reserved.
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Lúpus eritematoso sistêmico 
Doenças reumáticas
r e s u m o
Objetivo: Determinar a frequência de anticorpos antiparvovírus B19 (B19) em pacientes com 
artrite reumatoide (AR) e lúpus eritematoso sistêmico (LES), e a possível correlação da soro-
positividade anti-B19 com a atividade das doenças e a qualidade de vida. 
Pacientes e métodos: Foram utilizadas amostras séricas de 57 pacientes com AR, 45 com LES e 
65 controles sadios. Empregou-se protocolo com dados clínicos, os índices Disease Activity 
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Score 28 (DAS 28), Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) e Health 
Assessment Questionnaire (HAQ). Realizou-se a sorologia anti-B19 por ensaio imunoenzi-
mático (ELISA). 
Resultados: A média de idade dos pacientes foi de 42,74 +/- 14,09 anos, e a dos controles foi de 
38,38 +/- 13,42 anos. Tinham doença ativa 79 (77,5%) pacientes, e doença inativa 23 (22,5%). 
Anti-B19 (IgG) foi reagente em 49 (86,0%) IC 95% (77,0 – 95,0)% pacientes com AR, em 38 (84,4%) 
IC 95% (73,9 – 95,0)% com LES e em 40 (61,5%) IC 95% (49,7 – 73,4)% controles (p = 0,002). Anti-B19 
(IgM) foi reagente em 3 (5,3%) IC 95% (0,0 – 11,1)% pacientes com AR, em 7 (15,6%) IC 95% (5,0 
– 26,2)% pacientes com LES e em 1 (1,5%) IC 95% (0,0 – 4,5)% controle (p = 0,011). Não houve cor-
relação da reatividade anti-B19 com a atividade das doenças, os índices DAS 28, SLEDAI e HAQ. 
Conclusão: O presente estudo demonstrou que a população avaliada está exposta à infecção 
pelo B19, o que demanda atenção com suas manifestações, principalmente entre os pa-
cientes que apresentam maior risco, como os imunossuprimidos.
© 2014 Elsevier Editora Ltda. Todos os direitos reservados.
Introduction 
Human parvovirus B19 (B19), accidentally discovered in 
1974,1 is a small, non-enveloped, single strand DNA virus, 
family Parvoriridae, gender Erythrovirus. The viral particle 
has icosahedral symmetry, measuring between 22 and 24 
nanometers, composed of two structural (VP1 and VP2) and 
one nonstructural (NS1) protein. The VP1 protein represents 
less than 5% of the viral capsid, while VP2 protein corre-
sponds to more than 95%.2 B19 only infects humans, and 
its transmission occurs mainly by respiratory and transpla-
cental via. The transmission of B19 may occur occasionally, 
possibly through blood and blood products transfusions3 and 
organ transplants.4
B19 is the cause of erythema infectiosum (EI),5 and is also 
responsible for conditions of severe anemia in patients with 
hemolytic diseases such as sickle cell anemia,6,7 and bone 
marrow aplasia in immunocompromised hosts. 8.9 Further-
more, allegedly B19 is charged as the main agent of non-im-
mune hydrops fetalis, besides miscarriage and stillbirth.10-12
Some studies associate B19 to neurological diseases13,14 
and hearing loss,15 and this viral infection can cause pri-
marily manifestations that resemble those of autoimmune 
rheumatic diseases such as rashes, cytopenias, arthritis and 
autoantibodies.16-19 This makes it difficult to distinguish be-
tween B19 infection and autoimmune manifestations of the 
disease itself. At present, B19 is considered one of the pos-
sible agents of RA 20-22 and SLE23 in predisposed individuals.
Hedman and Franssila (2006) 21 reported that during the 
course of infection with B19, serum autoantibodies can be 
detected in some patients, as rheumatoid factor (RF), anti-
neutrophil cytoplasm (ANCA), anti-nuclear (ANA), anti-DNA, 
antimitochondrial (anti-M), antiphospholipid (anti-PL), anti-
Sm, anticardiolipin (aCL) and anticollagen autoantibodies. 
Other authors detected in the serum of patients with per-
sistent B19 infection, peptides homologous to those found 
in viral proteins and human cytokeratins, which favors the 
development of autoimmunity.24
Although some authors reported high levels of B19 in-
fection worldwide,25,26 most studies on this virus in patients 
with rheumatic diseases are conducted in European and 
Asian countries. In Latvia, 27an European country, a study 
evaluated the prevalence of B19 infection in patients with 
RA versus a control group of healthy blood donors, with anti-
B19 (IgG and IgM) serology by enzyme immunoassay (ELISA) 
and by a search of viral DNA in patients’ samples of plasma, 
peripheral blood leukocytes and cells of the synovial fluid, as 
well as in controls’ plasma and peripheral blood leukocytes. 
The result was the detection of anti-B19 (IgG) in 79% of pa-
tients’ plasma samples and in 77.7% of controls, and of anti-
B19 (IgM) in 24% of patients’ plasma samples and in 16% of 
controls. Viral DNA was detected in 16% of patients’ plasma 
samples and in 2.1% of controls (p = 0.00086), and in 18% of 
patients’ leukocytes and in 4.3% of controls (p = 0.0049) . The 
presence of B19 infection among patients with active and in-
active disease was similar. However, the presence of anti-B19 
(IgM) was shown to correlate with complications in clinical 
manifestations.
In a Taiwan study28 the authors investigated anti-B19 (IgG 
and IgM) antibodies and DNA in plasma and synovial fluid 
of RA patients and of healthy controls. The presence of anti-
B19 (IgG and/or IgM) in plasma was positive in 93.6% of pa-
tients and in 32.7% of controls (p <0.001), in 55.6% of samples 
of synovial fluid of patients and in 19.2% of samples from 
controls (p = 0.005). The viral DNA was positive in 30.6% of 
samples of plasma from patients and in 9.1% of controls (p 
= 0.005), and in 75.0% of synovial fluid samples of patients 
and in 26.9% of the controls (p = 0.015). Among patients with 
RA, a correlation between the presence of viral DNA and HLA 
DR4 was found.
In another study, it was demonstrated an association 
between presence of IgM anti-protein NS1 of B19 and cyclic 
citrullinated antipeptide IgG (anti-CCP) in patients with RA, 
particularly among those with persistent viral DNA in joint 
tissues. Moreover, the presence of anti-NS1 did not correlate 
with the activity index DAS 28.29
Due to a possible association between B19 infection and 
rheumatic diseases, and in view of the scarcity of studies on 
this virus in patients with RA and SLE in our scenario, we 
consider appropriate an investigation on this subject.
We also consider as relevant the evaluation of the staging 
of these diseases and the immune status in patients with RA 
and SLE affected by this viral infection, since the literature 
indicates the possibility of immunological changes caused 
by the virus.
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Objective
To evaluate the frequency of anti-B19 (IgG and IgM) in pa-
tients with RA and SLE compared with healthy controls, and 
to evaluate the possible correlation of anti-B19 seropositiv-
ity with disease activity, activity indexes (DAS 28 and SLEDAI) 
and quality of life (HAQ).
Patients and methods
167 volunteers were included in this study: 57 patients with 
RA and 45 with SLE treated at the Department of Rheuma-
tology, Hospital das Clínicas, Federal University of Goiás 
(UFG-HC), and a control group of 65 healthy volunteers. For 
inclusion in the study, patients had to fulfill the classifica-
tion criteria for RA of the American College of Rheumatol-
ogy (ACR),30 or, for SLE,31,32 could not present other rheumatic 
diseases, malignancies or any infectious disease, and should 
have > 18 years of age.
The activity of RA was assessed by Disease Activity Score 
28 (DAS 28),33 which considers active disease when its value 
exceeds 2.6, and quality of life was measured by the Health 
Assessment Questionnaire (HAQ).34 The activity of SLE was 
assessed by Systemic Lupus Erythematosus Disease Activity 
Index (SLEDAI),35 which considers the presence of active dis-
ease when the value is > 3.
The study of circulating anti-B19 antibodies (IgG and IgM) 
was performed by enzyme-linked immunosorbent assay (ELI-
SA) with parvovirus B19 RIDASCREEN kit, with sensitivity of 
91.3% for IgG and 91.7% for IgM, and with specificity of 97% 
for IgG and 93.8% for IgM, according to information from r-
biopharm, the reagent manufacturer. In the study of anti-B19 
(IgM) we employed a precipitant substance for removal of IgG 
antibodies and rheumatoid factor.
In statistical analysis, the chi square test, Fisher's exact 
test and logistic regression analysis were applied, using SPSS 
package version 15.0, considering as significant p values  <0.05 
and a confidence interval (CI) of 95%.
This study was reviewed and approved by the Research 
Ethics Committee at Hospital das Clínicas, Federal University 
of Goiás (UFG-CEP-HC), with the number 093/2010. All volun-
teers received due explanation on the procedures and signed 
the Informed Consent Form (ICF).
Results
Patients were aged 18 – 76 years with a mean of 42.74 ± 
14.09 years. The controls were aged 18 – 64 years with a 
mean of 38.38 ± 13.42 years. Among the 102 patients, 79 
(77.5%) had active disease, with 37 (46.8%) with SLE and 42 
(53.2%) with RA. The mean SLEDAI score between patients 
with SLE in activity was 9.92 ± 5.32. DAS 28 was calculated 
for 35 patients with RA activity, with a mean of 5.03 ± 1.19. 
The value of HAQ for 33 of these patients was determined, 
with a mean of 1.51 ± 0.91.
The search for circulating anti-B19 IgG was positive in 49 
(86.0%; CI 95% 77.0 – 95.0) RA patients, in 38 (84.4%; CI 95% 73, 
9 – 95.0) SLE patients and in 40 (61.5%; CI 95% 49.7 – 73.4) con-
trols (p = 0.002). The presence of anti-B19 (IgM) was observed 
in 3 (5.3%; CI 95% 0.0 – 11.1) RA patients, 7 (15.6%; CI 95% 5, 
0 – 26.2) SLE patients and 1 (1.5%; CI 95% 0.0 – 4.5) control (p = 
0.011) (Table 1).
The anti-B19 (IgG) reactivity was shown in 69 (87.3%; CI 
95% 80 – 94.7) patients with active disease and in 18 (78.3%; 
CI 95% 61,4 – 95.1) with inactive disease (p = 0.222). The anti-
B19 (IgM) reactivity occurred in 8 (10.1%; CI 95% 3.5 – 16.8) of 
patients with active disease and in 2 (8.7%; CI 95% 0.0 – 20.2) 
patients with inactive disease (p = 0.600) (Table 2).
In the evaluation of anti-B19 reactivity and of the index of 
activity in RA (DAS 28), it was observed that in those anti-B19 
(IgG) reactive (n = 32) patients, the mean DAS 28 was 4.98 ± 
1.15. In anti-B19 (IgG) nonreactive (n = 3) patients, the mean 
DAS 28 was 5.67 ± 1.65 (p = 0.340). When the anti-B19 reactiv-
ity (IgM) was evaluated, only one patient had this antibody, 
and the value of DAS 28 was 3.40. Among these anti-B19 IgM 
non-reactive (n = 34) patients, the mean DAS 28 was 5.08 ± 
1.17 (p = 0.237) (Table 3).
The quality of life index (HAQ) was calculated for 33 pa-
tients with active disease. Among these patients, 29 had anti-
B19 (IgG) reactive with a mean HAQ of 1.43 ± 0.92 and four had 
anti-B19 (IgG) non-reactive with a mean HAQ of 2.05 ± 0.71 
(p = 0.216). Anti-B19 (IgM) reactive was observed in only one 
patient with HAQ = 3.40 and anti-B19 (IgM) non-reactive in 32, 
with a mean HAQ of 1.54 ± 0.90 (p = 0.293) (Table 4).
Among SLE patients with active disease (n = 37), anti-B19 
(IgG) was reactive in 30 (81.1%) with a mean SLEDAI of 9.83 ± 
5.04, and among those with anti-B19 (IgG) non-reactive (n = 
7) (18.9%), the mean SLEDAI score was 9.94 ± 5.45 (p = 0.965). 
Table 1 – Frequency of anti-B19 (IgG and IgM) in patients with RA and SLE and controls in Goiânia, Goiás, between 
August 2010 and August 2011.
Anti-B19 IgG RA n (%) (CI 95%) SLE n (%) (CI 95%) Controls n (%) (CI 95%) p
+   49 (86.0) (77.0 - 95.0)   38 (84.4) (73.9 – 95.0)   40 (61.5) (49.7 – 73.4)
–   8 (14.0) (5.0 – 23.1)   7 (15.6) (5.0 – 26.1)   25 (38.5) (26.5 – 50.3)
Total   57 (100.0)   45 (100.0)   65 (100.0) 0.002
Anti-B19 IgM
+   3 (5.3) (0.0 – 11.1)   7 (15.6) (5.0 -26.7)   1 (1.5) (0.0 – 4.5)
–   54 (94.7) (88.9 – 100.0)   38 (84.4) (73.9 – 95.0)   64 (98.5) (95.5 – 100.0)
Total   57 (100.0)   45 (100.0)   65 (100.0) 0.011
Fisher exact test.
RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; B19, B19 parvovirus, IgG, Anti-B19 IgG; IgM, anti-B19 IgM; CI 95%, confidence 
interval 95%.
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Seven patients had anti-B19 (IgM) reactive, with a mean SLE-
DAI score of 9.63 ± 5.73. Among those with anti-B19 (IgM) 
non-reactive, the mean SLEDAI was 11.14 ± 5.28 (p = 0.496) 
(Table 5).
Discussion
This is the first Brazilian study on the frequency of anti-B19 
in SLE  and RA. In this study we investigated the presence of 
circulating antibodies in these patients, compared with the 
healthy population, and the possible influences of B19 infec-
tion in the clinical staging of these patients. In international 
publications, the inclusion of molecular studies reinforces the 
serological findings and points to evidence of the influence of 
this virus in the development of autoimmune diseases.
This study showed a high frequency of anti-B19 in the pop-
ulation evaluated, being greater among patients.
In this group of patients, the anti-B19 serology was not as-
sociated with presence of manifestations such as anemia, ar-
thritis, neuropathy and thyroiditis, nor with the development 
of autoantibodies.
The anti-B19 reactivity (IgG and IgM) observed in patients 
with RA and SLE in our geographical region was similar to 
that found in studies of Kozireva et al.,27 in Latvia, and of Chen 
et al.,28 in Taiwan, both evaluating patients with RA. These 
findings of high frequency of anti-B19 in patients with rheu-
matic diseases may result from a greater propensity, of these 
patients, in acquire viral infections due to immunosuppres-
sion or by some characteristic of the immune system in these 
patients, making them more susceptible to infection with this 
virus. Also, we cannot rule out the possibility of this virus act-
ing as a trigger for RA and SLE.
We are concerned about the fact of the persistence of viral 
DNA and the presence of IgM antibodies with respect to the 
diagnosis of infection, a relation with the autoimmune dis-
ease activity and the administration of immunosuppressive 
drugs. There is no definition about the risk of the presence of 
acute B19 infection and immunosuppressive therapy.
In the present study we found a correlation between an-
ti-B19 (IgG) reactivity and the rheumatic diseases evaluated, 
similar to that observed by Chen et al.,31 who, besides a corre-
lation between presence of antibodies and disease, also noted 
a correlation between presence of viral DNA in plasma and 
in synovial fluid of RA patients. In the evaluation of anti-B19 
reactivity (IgM), we noted a correlation only with SLE. The re-
sults found in this study were different from that observed 
by Kozireva et al.,30 who showed no correlation between the 
frequency of anti-B19 (IgG and IgM) and RA antibodies, but 
showed correlation when evaluating the presence of viral 
DNA in plasma, in synovial fluid and in peripheral blood leu-
kocytes.
The anti-B19 reactivity (IgG and IgM) in participants of the 
present study was not significantly associated with disease 
activity; this was also observed by Kozireva et al.30 This result 
suggests that the presence of large amounts of antibodies of 
the IgG class, as demonstrated in the two studies, prevented 
Table 2 – Frequency of anti-B19 (IgG and IgM) in patients 
with RA and SLE in activity in Goiânia, Goiás, between 
August 2010 and August 2011.
Anti-B19 
IgG
Activity YES  
(CI 95%)
Activity NO  
(CI 95%)
p
+ 69 (87.3)  (80.0-94.7) 18 (78.3) (61.4-95.1)
– 10 (12.7) (5.3-20.0) 5 (21.7)  (4.9-38.6)
Total 79 (100.0) 23 (100.0) 0.222
Anti-B19 IgM
+ 8 (10.1)  (3.5-16.8) 2 (8.7)  (0.0-20.2)
– 71 (89.9)  (83.2-96.5) 21 (91.3)  (79.8-100.0)
Total 79 (100.0) 23 (100.0) 0.600
Fisher exact test.
B19, B19 parvovirus; IgG, anti-B19 IgG; IgM, anti-B19 IgM; CI 95%, 
confidence interval 95%.
Table 3 – Frequency of anti-B19 (IgG and IgM) in patients 
with active RA and mean of DAS 28 in Goiânia, Goiás, 
between August 2010 and August 2011.
Anti-B19 IgG n DAS 28 Mean ± DP p
+ 32 (91.4) 4.98 +/- 1.15
– 3 (8.6) 5.67 +/- 1.65
Total 35 (100.0) 5.03 +/- 1.19 0.340
Anti-B19 IgM
+ 1 (2.9) 3.40
– 34 (97.1) 5.08 +/- 1.17
Total 35 (100.0) 5.03 +/- 1.19 0.237
Analysis of logistic regression.
DAS 28, Activity index for rheumatoid arthritis.
Table 4 – Frequency of anti-B19 (IgG and IgM) in patients 
with active RA and mean HAQ in Goiânia, Goiás, 
between August 2010 and August 2011.
Anti-B19 IgG n HAQ Mean ± DP p
+ 29 (87.9) 1.43 +/- 0.92
– 4 (12.1) 2.05 +/ 0.71
Total 33 (100.0) 1.51 +/- 0.91 0.216
Anti-B19 IgM
+ 1 (3.0) 0.30
– 32 (97.0) 1.54 +/- 0.90
Total 33 (100.0) 1.51 +/- 0.91 0.293
Analysis of logistic regression.
HAQ, Index of quality of life in rheumatoid arthritis.
Table 5 – Frequency of anti-B19 (IgG and IgM) in patients 
with active SLE and mean SLEDAI in Goiânia, Goiás, 
from August 2010 to August 2011.
Anti-B19 (IgG) n SLEDAI - mean ± DP p
+ 30 (81.1) 9.83 +/- 5.04
_ 7 (18.9) 9.94 +/- 5.45
Total 37 (100.0) 9.92 +/- 5.32 0.965
Anti-B19 (IgM)
+ 7 (18.9) 9.63 +/- 5.73
_ 30 (81.1) 11.14 +/- 5.28
Total 37 (100.0) 9.92 +/- 5.32 0.496
Analysis of logistic regression.
SLEDAI, Index of activity in systemic lupus erythematosus.
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that the virus, if present, alter the course of disease, and the 
disease was observed due to immune status of the individual 
patient or activity other factors not assessed, and not due to 
the presence of the virus in patients. 
In the present study we found no correlation between an-
ti-B19 (IgG and IgM) reactivity and activity indexes (DAS 28 
and SLEDAI) and quality of life (HAQ). These findings demon-
strate that the anti-B19 reactivities (IgG and IgM), indicators 
of previous and acute infection, respectively, did not corre-
late with clinical and laboratory aspects able to modify the 
indexes DAS 28, HAQ and SLEDAI. It is also possible that this 
high frequency of anti-B19 (IgG) reveal only that the studied 
population is constantly exposed to the presence of the virus 
without, however, apparent infection.
In a case report conducted  by Suzuki et al.,36 the authors 
reported the presence of B19 infection in a patient with SLE; 
its manifestation was similar to active disease, pointing in 
this publication the occurrence of common symptoms of 
acute infection and disease activity.
Studies published by Pavlovic et al.23 and Lunardi et al.24 
suggest the possibility of autoimmunity after B19 infection, 
due to similarities between molecules of this virus and host 
molecules. Furthermore, the work of Lunardi et al.24 suggested 
that manifestations similar to RA in patients infected with 
B19 may occur by deposition of viral antigen-antibody com-
plexes in these patients’ joints.
In the present study, low reactivity anti-B19 (IgM) was ob-
served, indicating recent infection, both among patients and 
controls. Although most patients with anti-B19 reactivity 
(IgM) exhibited disease activity, it was not possible to identify 
changes in these patients that could be attributed specifically 
to the viral action. On the other hand, acute infection, identi-
fied by the presence of anti-B19 (IgM), may have favored the 
reactivation of disease. Similar findings were observed by Hsu 
and Tsai,37 but with different findings in Kerr and Cuniff.38
In this study, we noted that the frequency of anti-B19 
(IgG) among controls, a healthy population, was similar to 
that found in Chilean blood donors,39 and higher than that 
observed in women of reproductive age in Goiânia, Goiás, Bra-
zil.40 These findings indicate that the frequency of prior in-
fection in the healthy population in our region is within the 
patterns observed in the literature.
 However , the finding of a higher frequency of reactivity 
observed among controls, compared with the study of Rios 
(2008),40 may be associated with a higher age group than the 
observed in the volunteers in our study. Another possibility 
is the constant presence of the volunteers in this study in 
a hospital setting, since they were mainly recruited among 
caregivers and blood donors. Also, we cannot rule out the dif-
ferent characteristics of the evaluated serum samples, since 
in our study we used freshly harvested samples, unlike the 
Rios study, who analyzed samples of sera bank.
Conclusion
In the present study, we demonstrated that the analyzed pop-
ulation is exposed to infection by B19; this finding demands 
attention with its manifestations, especially among immuno-
suppressed patients at greater risk of acquiring viral infections.
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